SG3 Management’s Quince Therapeutics QNCX Stock Holding History

SG3 Management’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-196	Closed	-$87K	–	410
2022 Q2	$87K	Hold	196	–	–	0.01%	331
2022 Q1	$242K	Buy	+196	New	+$267K	0.01%	731
2021 Q4	–	Sell	-63	Closed	-$1.15M	–	1234
2021 Q3	$1.15M	Sell	63 -662	-91%	-$10.5M	0.03%	430
2021 Q2	$7.68M	Hold	725	–	–	0.27%	78
2021 Q1	$5.22M	Buy	+725	New	+$5.22M	0.13%	172

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

SG3 Management's QNCX Position: Q4 2021 in Review

SG3 Management sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 45 shares — an estimated $825K sold.

SG3 Management first reported a position in QNCX in Q3 2021 and held it in 1 quarter. The position peaked at $825K in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

SG3 Management reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
SG3 Management sold 45 Quince Therapeutics shares in Q4 2021, an estimated $825K.
SG3 Management first reported a position in Quince Therapeutics in Q3 2021 and held it in 1 quarter.
SG3 Management's Quince Therapeutics position peaked at $825K in Q3 2021.
97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.